Autoimmunity in amyotrophic lateral sclerosis: Past and present

Neurology Research International

Volumn 2011, Issue , 2011, Pages

  Pagani, Mario Rafael ^a   Gonzalez, Laura Elisabeth ^b   Uchitel, Osvaldo Daniel ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865343114     PISSN: 20901852     EISSN: 20901860     Source Type: Journal    
DOI: 10.1155/2011/497080     Document Type: Review

References (149)

1. E. P. Simpson, D. Mosier, and S. H. Appel, "Mechanisms of disease pathogenesis in amyotrophic lateral sclerosis. A central role for calcium," Advances in Neurology, vol. 88, pp. 1-19, 2002.
2. M. J. Strong, "The basic aspects of therapeutics in amyotrophic lateral sclerosis," Pharmacology and Therapeutics, vol. 98, no. 3, pp. 379-414, 2003. (Pubitemid 36644160)
3. N. Nirmalananthan and L. Greensmith, "Amyotrophic lateral sclerosis: recent advances and future therapies," Current Opinion in Neurology, vol. 18, no. 6, pp. 712-729, 2005.
4. C. W. Lederer and N. Santama, "Amyotrophic lateral sclerosis- the tools of the trait," Biotechnology Journal, vol. 2, no. 5, pp. 608-621, 2007. (Pubitemid 46840049)
5. T. H. Siddique and X. Deng, "Genetics of amyotrophic lateral sclerosis," Human Molecular Genetics, vol. 5, pp. 1465-1470, 1996.
6. P. N. Valdmanis, H. Daoud, P. A. Dion, and G. A. Rouleau, "Recent advances in the genetics of amyotrophic lateral sclerosis," Current Neurology and Neuroscience Reports, vol. 9, no. 3, pp. 198-205, 2009.
7. J. Baumann, "Results of treatment of certain diseases of the central nervous system with ACTH and corticosteroids," Acta Neurologica Scandinavica. Supplementum, vol. 13, pp. 453-461, 1965.
8. I. Monstad, I. Dale, C. F. Petlund, and O. Sjaastad, "Plasma exchange in motor neuron disease. A controlled study," Journal of Neurology, vol. 221, no. 1, pp. 59-66, 1979. (Pubitemid 9245039)
9. M. R. Olarte, R. S. Schoenfeldt, G. McKiernan, and L. P. Rowland, "Plasmapheresis in amyotrophic lateral sclerosis," Annals of Neurology, vol. 8, no. 6, pp. 644-645, 1980.
10. R. H. Brown, S. L. Hauser, H. Harrington, and H. L. Weiner, "Failure of immunosuppression with a ten-to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis," Archives of Neurology, vol. 43, no. 4, pp. 383-384, 1986. (Pubitemid 16106958)
11. S. H. Appel, S. S. Stewart, V. Appel et al., "A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis," Archives of Neurology, vol. 45, no. 4, pp. 381-386, 1988. (Pubitemid 18098276)
12. D. B. Drachman, V. Chaudhry, D. Cornblath et al., "Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation," Annals of Neurology, vol. 35, no. 2, pp. 142-150, 1994. (Pubitemid 24050149)
13. E. G. McGeer and P. L. McGeer, "Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis," BioDrugs, vol. 19, no. 1, pp. 31-37, 2005. (Pubitemid 40432505)
14. J. I. Engelhardt, L. Siklos, L. Komuves, R. G. Smith, and S. H. Appel, "Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons," Synapse, vol. 20, no. 3, pp. 185-199, 1995.
15. L. Siklós, J. Engelhardt, Y. Harati, R. G. Smith, F. Joó, and S. H. Appel, "Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis," Annals of Neurology, vol. 39, no. 2, pp. 203-216, 1996. (Pubitemid 26071571)
16. A. H. Pullen and P. Humphreys, "Ultrastructural analysis of spinal motoneurones from mice treated with IgG from ALS patients, healthy individuals, or disease controls," Journal of the Neurological Sciences, vol. 180, no. 1-2, pp. 35-45, 2000.
17. A. H. Pullen, M. Demestre, R. S. Howard, and R. W. Orrell, "Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement," Acta Neuropathologica, vol. 107, no. 1, pp. 35-46, 2004. (Pubitemid 38088273)
18. M. R. Pagani, R. C. Reisin, and O. D. Uchitel, "Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals," Journal of Neuroscience, vol. 26, no. 10, pp. 2661-2672, 2006. (Pubitemid 43357849)
19. J. D. Rothstein, G. Tsai, R. W. Kuncl et al., "Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis," Annals of Neurology, vol. 28, no. 1, pp. 18-25, 1990. (Pubitemid 20222147)
20. J. D. Rothstein, L. J.Martin, and R.W. Kuncl, "Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis," New England Journal of Medicine, vol. 326, no. 22, pp. 1464-1468, 1992.
21. J. D. Rothstein, M. Van Kammen, A. I. Levey, L. J. Martin, and R.W. Kuncl, "Selective loss of glial glutamate transporter GLT-1 amyotrophic lateral sclerosis," Annals of Neurology, vol. 38, no. 1, pp. 73-84, 1995.
22. D. W. Cleveland and J. D. Rothstein, "From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS," Nature Reviews Neuroscience, vol. 2, no. 11, pp. 806-819, 2001. (Pubitemid 33674062)
23. L. Van Den Bosch, P. Van Damme, E. Bogaert, andW. Robberecht, "The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis," Biochimica et Biophysica Acta, vol. 1762, no. 11-12, pp. 1068-1082, 2006. (Pubitemid 44781176)
24. A. C. Bowling, J. B. Schulz, R. H. Brown Jr., and M. F. Beal, "Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 61, no. 6, pp. 2322-2325, 1993. (Pubitemid 23354097)
25. A. C. Bowling and M. F. Beal, "Bioenergetic and oxidative stress in neurodegenerative diseases," Life Sciences, vol. 56, no. 14, pp. 1151-1171, 1995.
26. D. Liu, "The roles of free radicals in amyotrophic lateral sclerosis," Journal of Molecular Neuroscience, vol. 7, no. 3, pp. 159-167, 1996. (Pubitemid 126718447)
27. S. E. Browne, A. C. Bowling, M. J. Baik, M. Gurney, R. H. Brown, and M. F. Beal, "Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 71, no. 1, pp. 281-287, 1998. (Pubitemid 28292560)
28. L. I. Bruijn, M. K. Houseweart, S. Kato et al., "Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1," Science, vol. 281, no. 5384, pp. 1851-1854, 1998. (Pubitemid 28450505)
29. A. Arai, M. Hasegawa, H. Akiyama et al., "TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis," Biochemical and Biophysical Research Communications, vol. 351, no. 3, pp. 602-611, 2006. (Pubitemid 44708852)
30. M. Neumann, D. M. Sampathu, L. K. Kwong et al., "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis," Science, vol. 314, no. 5796, pp. 130-133, 2006. (Pubitemid 44547757)
31. J. Sreedharan, I. P. Blair, V. B. Tripathi et al., "TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis," Science, vol. 319, no. 5870, pp. 1668-1672, 2008. (Pubitemid 351432505)
32. M. F. Beal, "Mitochondrial dysfunction in neurodegenerative diseases," Biochimica et Biophysica Acta, vol. 1366, no. 1-2, pp. 211-223, 1998. (Pubitemid 28467033)
33. M. Orth and A. H. V. Schapira, "Mitochondria and degenerative disorders," American Journal of Medical Genetics, vol. 106, no. 1, pp. 27-36, 2001. (Pubitemid 32601615)
34. O. D. Uchitel, S. H. Appel, F. Crawford, and L. Sczcupak, "Immunoglobulins from amyotrophic lateral sclerosis patients enhance spontaneous transmitter release from motor-nerve terminals," Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 19, pp. 7371-7374, 1988.
35. O. D. Uchitel, F. Scornik, D. A. Protti, C. G. Fumberg, V. Alvarez, and S. H. Appel, "Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins," Neurology, vol. 42, no. 11, pp. 2175-2180, 1992.
36. S. H. Appel, R. G. Smith, J. I. Engelhardt, and E. Stefani, "Evidence for autoimmunity in amyotrophic lateral sclerosis," Journal of theNeurological Sciences, vol. 124, pp. S14-S19, 1994.
37. S. A. Fratantoni, A. L. Dubrovsky, and O. D. Uchitel, "Uptake of immunoglobulin G from amyotrophic lateral sclerosis patients by motor nerve terminals in mice," Journal of the Neurological Sciences, vol. 137, no. 2, pp. 97-102, 1996. (Pubitemid 26172038)
38. S. A. Fratantoni, G. Weisz, A. M. Pardal, R. C. Reisin, and O. D. Uchitel, "Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker," Muscle and Nerve, vol. 23, no. 4, pp. 543-550, 2000. (Pubitemid 30164780)
39. J. P. Antel, B. G. Arnason, T. C. Fuller, and J. R. Lehrich, "Histocompatibility typing in amyotrophic lateral sclerosis," Archives of Neurology, vol. 33, no. 6, pp. 423-425, 1976.
40. M. B. Oldstone, C. B. Wilson, L. H. Perrin, and F. H. Norris Jr., "Evidence for immune-complex formation in patients with amyotrophic lateral sclerosis," Lancet, vol. 2, no. 7978, pp. 169-172, 1976.
41. S. H. Appel, V. Stockton-Appel, S. S. Stewart, and R. H. Kerman, "Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations," Archives of Neurology, vol. 43, no. 3, pp. 234-238, 1986. (Pubitemid 16117834)
42. E. J. Field and D. Hughes, "Toxicity of motor neurone disease serum for myelin in tissue culture," British Medical Journal, vol. 5475, pp. 1399-1401, 1965.
43. F. J. Roisen, H. Bartfeld, H. Donnenfeld, and J. Baxter, "Neuron specific in vitro cytotoxicity of sera from patients with amyotrophic lateral sclerosis," Muscle and Nerve, vol. 5, no. 1, pp. 48-53, 1982. (Pubitemid 12164825)
44. R. G. Smith, M. E. Alexianu, G. Crawford, O. Nyormoi, E. Stefanii, and S. H. Appel, "Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3393-3397, 1994. (Pubitemid 24130243)
45. M. S.Horwich,W. K. Engel, and P. B. Chauvin, "Amyotrophic lateral sclerosis sera applied to cultured motor neurons," Archives of Neurology, vol. 30, no. 4, pp. 332-333, 1974.
46. J. P. Mather and P. E. Roberts, Introduction to Cell and Tissue Culture: Theory and Technique, Plenum Press, San Francisco, Calif, USA, 1998.
47. R. P. Lisak, B. Zwiman, and M. Norman, "Antimyelin antibodies in neurologic diseases. Immunofluorescent demonstration," Archives of Neurology, vol. 32, no. 3, pp. 163-167, 1975.
48. J. Liveson, H. Frey, and M. B. Bornstein, "The effect of serum from ALS patients on organotypic nerve and muscle tissue cultures," Acta Neuropathologica, vol. 32, no. 2, pp. 127-131, 1975.
49. B. Li, X. Y. Liu, Z. Li et al., "Effect of ALS IgG on motor neurons in organotypic spinal cord cultures," Canadian Journal of Neurological Sciences, vol. 35, no. 2, pp. 220-225, 2008. (Pubitemid 351831061)
50. D. W. Mulder, E. H. Lambert, and L. M. Eaton, "Myasthenic syndrome in patients with amyotrophic lateral sclerosis," Neurology, vol. 9, pp. 627-631, 1959.
51. E. H. Denys and F. H. Norris Jr., "Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission," Archives of Neurology, vol. 36, no. 4, pp. 202-205, 1979. (Pubitemid 9125324)
52. R. A.Maselli, R. L.Wollman, C. Leung et al., "Neuromuscular transmission in amyotrophic lateral sclerosis," Muscle and Nerve, vol. 16, no. 11, pp. 1193-1203, 1993. (Pubitemid 23304857)
53. T. Yoshihara, T. Ishii, M. Iwata, andM. Nomoto, "Ultrastructural and histochemical study of the motor end plates of the intrinsic laryngeal muscles in amyotrophic lateral sclerosis," Ultrastructural Pathology, vol. 22, no. 2, pp. 121-126, 1998. (Pubitemid 28234872)
54. L. R. Fischer, D. G. Culver, P. Tennant et al., "Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man," Experimental Neurology, vol. 185, no. 2, pp. 232-240, 2004. (Pubitemid 38084849)
55. S. H. Appel, J. I. Engelhardt, J. Garcá, and E. Stefani, "Autoimmunity and ALS: A comparison of animal models of immune-mediated motor neuron destruction and human ALS," Advances in Neurology, vol. 56, pp. 405-412, 1991.
56. T. J. O'Shaughnessy, H. Yan, J. Kim et al., "Amyotrophic lateral sclerosis: serumfactors enhance spontaneous and evoked transmitter release at the neuromuscular junction," Muscle and Nerve, vol. 21, no. 1, pp. 81-90, 1998. (Pubitemid 28041684)
57. H. A.Mohamed,D. R.Mosier, L. L. Zou et al., "Immunoglobulin Fc ? receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons," Journal of Neuroscience Research, vol. 69, no. 1, pp. 110-116, 2002. (Pubitemid 34734171)
58. S. Muchnik, A. Losavio, and S. D. Lorenzo, "Effect of amyotrophic lateral sclerosis serum on calcium channels related to spontaneous acetylcholine release," Clinical Neurophysiology, vol. 113, no. 7, pp. 1066-1071, 2002. (Pubitemid 34667144)
59. L. P. Bernstein and J. P. Antel, "Motor neuron disease: decremental responses to repetitive nerve stimulation," Neurology, vol. 31, no. 2, pp. 204-207, 1981. (Pubitemid 11137606)
60. K. R. Sharma, J. A. Kent-Braun, S. Majumdar et al., "Physiology of fatigue in amyotrophic lateral sclerosis," Neurology, vol. 45, no. 4, pp. 733-740, 1995.
61. D. A. Protti, R. C. Reisin, T. A. Mackinley, and O. D. Uchitel, "Calcium channel blockers and transmitter release at the normal human neuromuscular junction," Neurology, vol. 46, no. 5, pp. 1391-1396, 1996. (Pubitemid 26159303)
62. E. Katz, P. A. Ferro, G. Weisz, and O. D. Uchitel, "Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction," Journal of Physiology, vol. 497, no. 3, pp. 687-697, 1996. (Pubitemid 27032907)
63. R. Pagani, M. Song, M. Mcenery et al., "Differential expression of alpha 1 and beta subunits of voltage dependent Ca2+ channel at the neuromuscular junction of normal and P/Q Ca2+ channel knockout mouse," Neuroscience, vol. 123, no. 1, pp. 75-85, 2004. (Pubitemid 37518477)
64. Y. Sugiura and C. Ko, "Novel modulatory effect of L-type calcium channels at newly formed neuromuscular junctions," Journal of Neuroscience, vol. 17, no. 3, pp. 1101-1111, 1997. (Pubitemid 27043968)
65. M. D. Rosato Siri and O. D. Uchitel, "Calcium channels coupled to neurotransmitter release at neonatal rat neuromuscular junctions," Journal of Physiology, vol. 514, no. 2, pp. 533-540, 1999. (Pubitemid 29055979)
66. M. M. Santafé, F. J. Urbano,M. A. Lanuza, and O. D. Uchitel, "Multiple types of calcium channels mediate transmitter release during functional recovery of botulinum toxin type A-poisoned mousemotor nerve terminals," Neuroscience, vol. 95, no. 1, pp. 227-234, 2000.
67. J. I. Engelhardt, S. H. Appel, and J. M. Killian, "Experimental autoimmune motoneuron disease," Annals of Neurology, vol. 26, no. 3, pp. 368-376, 1989. (Pubitemid 19230306)
68. J. I. Engelhardt and S. H. Appel, "IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis," Archives of Neurology, vol. 47, no. 11, pp. 1210-1216, 1990. (Pubitemid 20381002)
69. J. I. Engelhardt, J. Soós, I. Obál, L. Vigh, and L. Siklós, "Subcellular localization of IgG from the sera of ALS patients in the nervous system," Acta Neurologica Scandinavica, vol. 112, no. 2, pp. 126-133, 2005. (Pubitemid 41003373)
70. D. L. Price, J. Griffin, A. Young, K. Peck, and A. Stocks, "Tetanus toxin: direct evidence for retrograde intraaxonal transport," Science, vol. 188, no. 4191, pp. 945-947, 1975.
71. K. C. Joseph, S.U. Kim, A. Stieber, and N. K. Gonatas, "Endocytosis of cholera toxin into neuronal GERL," Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 6, pp. 2815-2819, 1978. (Pubitemid 8374999)
72. R. H. Fabian, "Uptake of plasma IgG by CNS motoneurons: comparison of antineuronal and normal IgG," Neurology, vol. 38, no. 11, pp. 1775-1780, 1988. (Pubitemid 18265046)
73. B. Arvidson, "Accumulation of inorganic mercury in lower motoneurons of mice," NeuroToxicology, vol. 13, no. 1, pp. 277-280, 1992.
74. M. Demestre, A. Pullen, R. W. Orrell, and M. Orth, "ALSIgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures," Journal of Neurochemistry, vol. 94, no. 1, pp. 268-275, 2005. (Pubitemid 40911412)
75. M. E. Alexianu, B. K. Ho, A. H. Mohamed, V. La Bella, R. G. Smith, and S. H. Appel, "The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis," Annals of Neurology, vol. 36, no. 6, pp. 846-858, 1994. (Pubitemid 24370923)
76. F. H. Yi, C. Lautrette, C. Vermot-Desroches et al., "In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients," Journal of Neuroimmunology, vol. 109, no. 2, pp. 211-220, 2000.
77. A. B. Parkes, C. R. Rickards, P. Rees, and M. F. Scanlon, "Cytotoxic changes in A172 glioblastoma cells exposed to serum Ig from patients with motor neurone disease," Journal of the Neurological Sciences, vol. 129, pp. S136-S137, 1995.
78. O. Delbono, J. Garcia, S. H. Appel, and E. Stefani, "Calcium current and charge movement of mammalian muscle: action of amyotrophic lateral sclerosis immunoglobulins," Journal of Physiology, vol. 444, pp. 723-742, 1991.
79. R. G. Smith, S.Hamilton, F.Hofmann et al., "Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis," New England Journal of Medicine, vol. 327, no. 24, pp. 1721-1728, 1992.
80. F. Kimura, R. G. Smith, O. Delbono et al., "Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel ? subunit," Annals of Neurology, vol. 35, no. 2, pp. 164-171, 1994.
81. B. Katz and R. Miledi, "Further study of the role of calcium in synaptic transmission," Journal of Physiology, vol. 207, no. 3, pp. 789-801, 1970.
82. G. J. Augustine, M. P. Charlton, and S. J. Smith, "Calcium action in synaptic transmitter release," Annual Review of Neuroscience, vol. 10, pp. 633-693, 1987. (Pubitemid 17022784)
83. R. G.Miller, S. A. Smith, J. R.Murphy et al., "A clinical trial of verapamil in amyotrophic lateral sclerosis," Muscle and Nerve, vol. 19, no. 4, pp. 511-515, 1996. (Pubitemid 26104302)
84. R. G. Miller, R. Shepherd, H. Dao et al., "Controlled trial of nimodipine in amyotrophic lateral sclerosis," Neuromuscular Disorders, vol. 6, no. 2, pp. 101-104, 1996. (Pubitemid 26073991)
85. O. D. Uchitel, D. A. Protti, V. Sanchez, B. D. Cherksey, M. Sugimori, and R. Llinas, "P-type voltage-dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 8, pp. 3330-3333, 1992.
86. D. A. Protti, L. Szczupak, F. S. Scornik, and O. D. Uchitel, "Effect of conotoxin GVIA on neurotransmitter release at themouse neuromuscular junction," Brain Research, vol. 557, no. 1-2, pp. 336-339, 1991.
87. E. Katz, P. A. Ferro, B. D. Cherksey,M. Sugimori, R. Llinás, and O. D. Uchitel, "Effects of Ca2+ channel blockers on transmitter release and presynaptic currents at the frog neuromuscular junction," Journal of Physiology, vol. 486, no. 3, pp. 695-706, 1995.
88. P. P. Perissinotti, B. G. Tropper, and O. D. Uchitel, "L-type calcium channels are involved in fast endocytosis at the mouse neuromuscular junction," European Journal of Neuroscience, vol. 27, no. 6, pp. 1333-1344, 2008. (Pubitemid 351406270)
89. O. Nyormoi, "Proteolytic activity in amyotrophic lateral sclerosis IgG preparations," Annals of Neurology, vol. 40, no. 5, pp. 701-706, 1996. (Pubitemid 26415181)
90. M. Demestre, R. S. Howard, R. W. Orrell, and A. H. Pullen, "Serine proteases purified from sera of patients with amyotrophic lateral sclerosis (ALS) induce contrasting cytopathology in murine motoneurones to IgG," Neuropathology and Applied Neurobiology, vol. 32, no. 2, pp. 141-156, 2006.
91. R. Llinas, M. Sugimori, B. D. Cherksey et al., "IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11743-11747, 1993. (Pubitemid 24008715)
92. A. B. Zhainazarov, P. Annunziata, S. Toneatto, E. Cherubini, and A. Nistri, "Serum fractions from amyotrophic lateral sclerosis patients depress voltage-activated Ca2+ currents of rat cerebellar granule cells in culture," Neuroscience Letters, vol. 172, no. 1-2, pp. 111-114, 1994.
93. J. R. Carter and M. Mynlieff, "Amyotrophic lateral sclerosis patient IgG alters voltage dependence of Ca2+ channels in dissociated rat motoneurons," Neuroscience Letters, vol. 353, no. 3, pp. 221-225, 2003. (Pubitemid 37510182)
94. D. R. Mosier, P. Baldelli, O. Delbono et al., "Amyotrophic lateral sclerosis immunoglobulins increase Ca2+ currents in a motoneuron cell line," Annals of Neurology, vol. 37, no. 1, pp. 102-109, 1995.
95. H. D. Yan, W. Lim, K. W. Lee, and J. Kim, "Sera from amyotrophic lateral sclerosis patients reduce high-voltage activated Ca2+ currents in mice dorsal root ganglion neurons," Neuroscience Letters, vol. 235, no. 1-2, pp. 69-72, 1997. (Pubitemid 27471107)
96. W. A. Catterall, "Structure and regulation of voltage-gated Ca2+ channels," Annual Review of Cell and Developmental Biology, vol. 16, pp. 521-555, 2000. (Pubitemid 32037516)
97. E. M. Fitzgerald and A. C. Dolphin, "Regulation of rat neuronal voltage-dependent calcium channels by endogenous p21-ras," European Journal of Neuroscience, vol. 9, no. 6, pp. 1252-1261, 1997. (Pubitemid 27260754)
98. S. W. Martin, A. J. Butcher, N. S. Berrow et al., "Phosphorylation sites on calcium channel ?1 and ? subunits regulate ERK-dependent modulation of neuronal N-type calcium channels," Cell Calcium, vol. 39, no. 3, pp. 275-292, 2006. (Pubitemid 43159772)
99. D. B. Drachman, P. S. Fishman, J. D. Rothstein et al., "Amyotrophic lateral sclerosis. An autoimmune disease?" Advances in Neurology, vol. 68, pp. 59-65, 1995.
100. C. Arsac, C. Raymond, N.Martin-Moutot et al., "Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum," Annals of Neurology, vol. 40, no. 5, pp. 695-700, 1996. (Pubitemid 26415180)
101. A. Pestronk, R. N. Adams, L. Clawson et al., "Serum antibodies to GM ganglioside in amyotrophic lateral sclerosis," Neurology, vol. 38, no. 9, pp. 1457-1461, 1988.
102. G. Ordonez and J. Sotelo, "Antibodies against fetal muscle proteins in serum from patients with amyotrophic lateral sclerosis," Neurology, vol. 39, no. 5, pp. 683-686, 1989. (Pubitemid 19126967)
103. A. Greiner, A.Marx,H. K.Muller-Hermelink, B. Schmausser, K. Petzold, and H. Kruger, "Vascular autoantibodies in amyotrophic lateral sclerosis," Lancet, vol. 340, no. 8815, pp. 378-379, 1992.
104. P. Couratier, F. H. Yi, J. L. Preud'homme et al., "Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis," Journal of the Neurological Sciences, vol. 154, no. 2, pp. 137-145, 1998. (Pubitemid 28156929)
105. I. Niebroj-Dobosz, D. Dziewulska, and P. Janik, "Autoantibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS)," Folia Neuropathologica, vol. 44, no. 3, pp. 191-196, 2006. (Pubitemid 44613893)
106. L. Fialová, J. ?Svarcová, A. Bartos et al., "Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis," European Journal of Neurology, vol. 17, no. 4, pp. 562-566, 2010.
107. C. Raoul, A. G. Estévez, H. Nishimune et al., "Motoneuron death triggered by a specific pathway downstream of fas: potentiation by ALS-linked SOD1 mutations," Neuron, vol. 35, no. 6, pp. 1067-1083, 2002. (Pubitemid 35279535)
108. Z. Q. Xiong and J. O. McNamara, "Fas(t) balls and Lou Gehrig disease: A clue to selective vulnerability of motor neurons?" Neuron, vol. 35, no. 6, pp. 1011-1013, 2002. (Pubitemid 35279528)
109. S. Naor, Z. Keren, T. Bronshtein, E. Goren, M. MacHluf, and D. Melamed, "Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes," Journal of Neurology, vol. 256, no. 8, pp. 1228-1235, 2009.
110. E. Tüzün and J. Dalmau, "Limbic encephalitis and variants: classification, diagnosis and treatment," Neurologist, vol. 13, no. 5, pp. 261-271, 2007. (Pubitemid 47396312)
111. S. Orrenius, B. Zhivotovsky, and P. Nicotera, "Regulation of cell death: The calcium-apoptosis link," Nature Reviews Molecular Cell Biology, vol. 4, no. 7, pp. 552-565, 2003. (Pubitemid 36773407)
112. M. M. Thomas and S. M. J. Dunn, "Amyotrophic lateral sclerosis immunoglobulins are ineffective in altering calcium influx through presynaptic voltage-sensitive calcium channels," Neurological Research, vol. 19, no. 2, pp. 129-134, 1997. (Pubitemid 27190701)
113. L. Xu, Y. S. Guo, Y. L. Liu et al., "Oxidative stress in immunemediated motoneuron destruction," Brain Research, vol. 1302, pp. 225-232, 2009.
114. D. Troost, J. J. Van den Oord, J. M. de Jong, and D. F. Swaab, "Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis," Clinical Neuropathology, vol. 8, no. 6, pp. 289-294, 1989. (Pubitemid 20101117)
115. D. Troost, N. Claessen, J. J. Van den Oord, D. F. Swaab, and J. M. de Jong, "Neuronophagia in the motor cortex in amyotrophic lateral sclerosis," Neuropathology and Applied Neurobiology, vol. 19, no. 5, pp. 390-397, 1993. (Pubitemid 23304875)
116. H. Bartfeld, C. Dham, and H. Donnenfeld, "Immunoregulatory and activated T cells in amyotrophic lateral sclerosis patients," Journal of Neuroimmunology, vol. 9, no. 3-4, pp. 131-137, 1985. (Pubitemid 15072995)
117. W. M. H. Behan and P. O. Behan, "Recent advances in polymyositis," Italian Journal of Neurological Sciences, vol. 5, no. 1, pp. 23-31, 1984. (Pubitemid 14117189)
118. D. Troost, J. J. Van den Oord, and J. M. Vianney de Jong, "Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis," Neuropathology and Applied Neurobiology, vol. 16, no. 5, pp. 401-410, 1990. (Pubitemid 20334861)
119. J. I. Engelhardt, J. Tajti, and S. H. Appel, "Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis," Archives of Neurology, vol. 50, no. 1, pp. 30-36, 1993. (Pubitemid 23019197)
120. M. C. Graves, M. Fiala, L. A. V. Dinglasan et al., "Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells," Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 5, no. 4, pp. 213-219, 2004. (Pubitemid 40125187)
121. M. Rentzos, A. Rombos, C. Nikolaou et al., "Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: A reflection of Th17 cells activation?" Acta Neurologica Scandinavica, vol. 122, no. 6, pp. 425-429, 2010.
122. J. S. Henkel, J. I. Engelhardt, L. Siklós et al., "Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue," Annals of Neurology, vol. 55, no. 2, pp. 221-235, 2004. (Pubitemid 38166999)
123. J. S. Henkel, D. R. Beers, L. Siklós, and S. H. Appel, "The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS," Molecular and Cellular Neuroscience, vol. 31, no. 3, pp. 427-437, 2006. (Pubitemid 43358017)
124. M. E. Alexianu, M. Kozovska, and S. H. Appel, "Immune reactivity in a mouse model of familial ALS correlates with disease progression, "Neurology, vol. 57, no. 7, pp. 1282-1289, 2001. (Pubitemid 32947389)
125. A. J. Kornberg and A. Pestronk, "Chronic motor neuropathies: diagnosis, therapy, and pathogenesis," Annals of Neurology, vol. 37, no. 1, pp. S43-S50, 1995.
126. M. Roberts, H. J.Willison, A. Vincent, and J. Newsom-Davis, "Multifocal motor neuropathy human sera block distal motor nerve conduction in mice," Annals of Neurology, vol. 38, no. 1, pp. 111-118, 1995.
127. J. Newsom-Davis, "High hopes .. for neurology. A view from the top," Journal of the Royal College of Physicians of London, vol. 28, no. 2, p. 105, 1994.
128. M. Swash, "We have a problem: why have ALS trials been negative?" Amyotrophic Lateral Sclerosis, vol. 8, no. 5, p. 259, 2007. (Pubitemid 47543088)
129. F. Fornai, P. Longone, L. Cafaro et al., "Lithium delays progression of amyotrophic lateral sclerosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2052-2057, 2008. (Pubitemid 351439463)
130. V. Meininger, J. Shefner, and M. Cudkowicz, "Lithium therapy in ALS," Amyotrophic Lateral Sclerosis, vol. 9, no. 2, p. 122, 2008. (Pubitemid 351584039)
131. R. S. Bedlack, N. Maragakis, and T. Heiman-Patterson, "Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 16, p. E17, 2008. (Pubitemid 351758376)
132. A. Gill, J. Kidd, F. Vieira, K. Thompson, and S. Perrin, "No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS," PLoS ONE, vol. 4, no. 8, Article ID e6489, 2009.
133. R. G. Smith and S. H. Appel, "Immunosuppression and antiinflammatory agents in ALS," Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 1, supplement 4, pp. 33-43, 2000.
134. A. A. Rossini, "Autoimmune diabetes and the circle of tolerance," Diabetes, vol. 53, no. 2, pp. 267-275, 2004. (Pubitemid 38174540)
135. M. Dib, "Amyotrophic lateral sclerosis: progress and prospects for treatment," Drugs, vol. 63, no. 3, pp. 289-310, 2003. (Pubitemid 36197501)
136. M. E. Cudkowicz, J. M. Shefner, D. A. Schoenfeld et al., "Trial of celecoxib in amyotrophic lateral sclerosis," Annals of Neurology, vol. 60, no. 1, pp. 22-31, 2006.
137. B. R. Brooks, "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee onMotor Neuron Diseases/Amyotrophic Lateral Sclerosis of theWorld Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors," Journal of the Neurological Sciences, vol. 124, pp. 96-107, 1994.
138. K. Ekbom, "The man behind the syndrome: Jean-Martin Charcot," Journal of the History of the Neurosciences, vol. 1, no. 1, pp. 39-45, 1992.
139. P. G. Ince, J. Slade, R.M. Chinnery et al., "Quantitative study of synaptophysin immunoreactivity of cerebral cortex and spinal cord inmotor neuron disease," Journal of Neuropathology and Experimental Neurology, vol. 54, no. 5, pp. 673-679, 1995.
140. V. A. Cwik, C. C. Hanstock, P. S. Allen, and W. R. Martin, "Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy," Neurology, vol. 50, no. 1, pp. 72-77, 1998. (Pubitemid 28106022)
141. K. Arasaki, Y. Kato, A. Hyodo, R. Ushijima, and M. Tamaki, "Longitudinal study of functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis," Muscle and Nerve, vol. 25, no. 4, pp. 520-526, 2002. (Pubitemid 34293126)
142. A. Vincent, "Immunology of the neuromuscular junction and presynaptic nerve terminal," Current Opinion in Neurology, vol. 12, no. 5, pp. 545-551, 1999. (Pubitemid 30028614)
143. J. M. Shefner, A. G. Reaume, D. G. Flood et al., "Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy," Neurology, vol. 53, no. 6, pp. 1239-1246, 1999. (Pubitemid 29480082)
144. S. Ranganathan, E. Williams, P. Ganchev et al., "Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis," Journal of Neurochemistry, vol. 95, no. 5, pp. 1461-1471, 2005. (Pubitemid 41779269)
145. R. Bowser, M. Cudkowicz, and R. Kaddurah-Daouk, "Biomarkers for amyotrophic lateral sclerosis," Expert Review of Molecular Diagnostics, vol. 6, no. 3, pp. 387-398, 2006. (Pubitemid 44174343)
146. L. J. McCawley and L. M. Matrisian, "Matrix metalloproteinases: they're not just formatrix anymore!," Current Opinion in Cell Biology, vol. 13, no. 5, pp. 534-540, 2001. (Pubitemid 32817010)
147. M. Demestre, G. Parkin-Smith, A. Petzold, and A. H. Pullen, "The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis," Journal of Neuroimmunology, vol. 159, no. 1-2, pp. 146-154, 2005. (Pubitemid 40136512)
148. L. Fang, M. Teuchert, F. Huber-Abel et al., "MMP-2 and MMP-9 are elevated in spinal cord and skin in amouse model of ALS," Journal of the Neurological Sciences, vol. 294, no. 1-2, pp. 51-56, 2010.
149. K. Gwinn, R. A. Corriveau, H. Mitsumoto et al., "Amyotrophic lateral sclerosis: an emerging era of collaboratie gene discovery," PLoS ONE, vol. 2, no. 12, Article ID e1254, 2007.